What Happened?
Shares of medical device company DexCom (NASDAQ: DXCM) fell 14.8% in the afternoon session after the company reported underwhelming earnings.
The company's revenue grew over 21% year-on-year to $1.21 billion, and its adjusted earnings per share of $0.61 also came in ahead of consensus estimates. DexCom lifted its full-year 2025 revenue forecast to approximately $4.64 billion. Despite these positive metrics, the stock's decline suggests investors were anticipating an even more robust performance and a more substantial guidance increase. The market's negative reaction indicates that the strong quarter was not enough to meet the high expectations priced into the stock, prompting a sell-off.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy DexCom? Access our full analysis report here.
What Is The Market Telling Us
DexCom’s shares are quite volatile and have had 15 moves greater than 5% over the last year. But moves this big are rare even for DexCom and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 21 days ago when the stock dropped 3.7% on the news that worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling a meeting with President Xi caused a rapid sell-off in the market. The trade dispute flared up after China imposed export controls on rare earth minerals, which are critical components for high-tech manufacturing. The escalation of the trade war raises concerns about supply chain disruptions and increased costs for technology companies, which are heavily reliant on global trade, leading to a broad sell-off in the sector.
DexCom is down 24.8% since the beginning of the year, and at $59.01 per share, it is trading 35% below its 52-week high of $90.75 from February 2025. Investors who bought $1,000 worth of DexCom’s shares 5 years ago would now be looking at an investment worth $756.54.
While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our full research report.
